Detalhe da pesquisa
1.
The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond.
Gastroenterology
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754739
2.
Safety, feasibility, and impact on the gut microbiome of kefir administration in critically ill adults.
BMC Med
; 22(1): 80, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38378568
3.
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.
J Infect Dis
; 228(10): 1452-1455, 2023 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37540090
4.
Bile Acid Sequestrants in Microscopic Colitis: Clinical Outcomes and Utility of Bile Acid Testing.
Clin Gastroenterol Hepatol
; 21(12): 3125-3131.e2, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37172800
5.
Reduction in urinary tract infections in patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection.
Eur J Clin Microbiol Infect Dis
; 42(8): 1037-1041, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37351724
6.
Outcomes of Fecal Microbiota Transplantation for C. difficile Infection in Inflammatory Bowel Disease : A Systematic Review and Meta-analysis.
J Clin Gastroenterol
; 57(3): 285-293, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34864789
7.
Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease.
J Gastroenterol Hepatol
; 38(11): 1910-1916, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37337469
8.
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.
JAMA
; 329(16): 1356-1366, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37060545
9.
Fatty liver and cerebrovascular disease: plausible association and possible mechanisms.
Curr Opin Lipidol
; 33(1): 31-38, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34799486
10.
Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
Gastroenterology
; 160(6): 1961-1969.e3, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33444573
11.
The Epidemiology of Microscopic Colitis in Olmsted County, Minnesota: Population-Based Study From 2011 to 2019.
Clin Gastroenterol Hepatol
; 20(5): 1085-1094, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34216819
12.
Microscopic Colitis and Risk of Colon Adenomas: A Multicenter Retrospective Cohort Study.
Clin Gastroenterol Hepatol
; 20(4): e902-e904, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34062313
13.
Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry.
Gastroenterology
; 160(1): 183-192.e3, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33011173
14.
Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile From a Population-Based Study.
Am J Gastroenterol
; 117(8): 1311-1315, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35417427
15.
Postinfection Irritable Bowel Syndrome Following Clostridioides difficile Infection: A Systematic-review and Meta-analysis.
J Clin Gastroenterol
; 56(2): e84-e93, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34049374
16.
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
BMC Infect Dis
; 22(1): 245, 2022 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35279084
17.
Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection.
Dig Dis Sci
; 67(7): 2763-2770, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34275058
18.
Durability of Response to Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence in Patients With Clostridioides difficile Infection.
Clin Infect Dis
; 73(7): e1706-e1712, 2021 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32976567
19.
RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections.
Clin Infect Dis
; 73(7): e1613-e1620, 2021 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966574
20.
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
Clin Infect Dis
; 72(12): 2132-2140, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32255488